-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TUKPiLOPNCam+/vIGDhkpVcW5HmzkgsIYZ2K89Qp2rdnSfOntil/HFSIDrK54207 JjE94ZLnTa95vUMaZRba5Q== 0001104659-07-076060.txt : 20071022 0001104659-07-076060.hdr.sgml : 20071022 20071022124537 ACCESSION NUMBER: 0001104659-07-076060 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20071022 DATE AS OF CHANGE: 20071022 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 071182727 BUSINESS ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 02494 BUSINESS PHONE: 7814330771 MAIL ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 021942725 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 02494 BUSINESS PHONE: 7814330771 MAIL ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 021942725 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 425 1 a07-27173_5425.htm 425

Filed by AVANT Immunotherapeutics, Inc.

Pursuant to Rule 425 under Securities Act of 1933, as amended

 

Subject Company: AVANT Immunotherapeutics, Inc.

Subject Company’s Commission File No.: 000-015006

 

AVANT E-mail to employees – to be sent at 6:50 a.m.

 

Subject: Press release to be issued at 6:55 a.m. this morning; Company meeting to follow at 10:00 a.m.

 

Dear AVANT Employees:

 

This morning at 6:55 a.m. a press release will be issued announcing the merger of AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. to create a diversified biopharmaceutical company with a deep product development pipeline. We want to let our team members know about this exciting and transformative event. You will receive the press release plus additional background material immediately following the news entering the public domain. We will hold a Company meeting at 10:00 a.m. today in the Needham Seminar Room and by phone with Fall River team members.

 

I look forward to talking with you in detail and answering your questions about this exciting merger as we work to build the future of our Company. I want to thank each of you for your contributions to AVANT that have made this promising new company possible. We anticipate a productive future and I look forward to the successes we will enjoy together.

 

Una

 

Forward Looking Statements and Participants in the Solicitation

 

This communication contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements are subject to risks and uncertainties that may cause actual future experience and results to differ materially from those discussed in these forward-looking statements.

 

This communication may be deemed to be solicitation material in respect of the proposed merger of AVANT and Celldex. The directors and executive officers of AVANT and Celldex may be deemed to be participants in the solicitation of proxies from the holders of AVANT common stock in respect of the proposed transaction. In connection with the proposed merger, AVANT and Celldex intend to file relevant materials with the SEC, including AVANT’s joint registration statement/proxy statement on Form S-4. SHAREHOLDERS OF AVANT ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING AVANT’S PROXY STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

 

Follow-up e-mail to be sent immediately following confirmation of the release crossing the wire

 

Subject: AVANT/Celldex merger press release and fact sheet on AVANT/Celldex

 

Dear AVANT Employees:

 

Attached, please find a copy of the press release issued this morning announcing the proposed merger of AVANT and Celldex and a fact sheet providing an overview of the new combined

 


 

company. You may also wish to visit our website or the Celldex website at www.celldextherapeutics.com for more information which will be posted in the near future.

 

I will be joined in our 10:00 meeting by Anthony Marucci, current Vice President and Chief Financial Officer of Celldex and future Executive Vice President of AVANT/Celldex. We look forward to seeing you then.

 

Una

 

Forward Looking Statements and Participants in the Solicitation

 

This communication contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements are subject to risks and uncertainties that may cause actual future experience and results to differ materially from those discussed in these forward-looking statements.

 

This communication may be deemed to be solicitation material in respect of the proposed merger of AVANT and Celldex. The directors and executive officers of AVANT and Celldex may be deemed to be participants in the solicitation of proxies from the holders of AVANT common stock in respect of the proposed transaction. In connection with the proposed merger, AVANT and Celldex intend to file relevant materials with the SEC, including AVANT’s joint registration statement/proxy statement on Form S-4. SHAREHOLDERS OF AVANT ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING AVANT’S PROXY STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

 

 -----END PRIVACY-ENHANCED MESSAGE-----